Results 151 to 160 of about 38,575 (293)

Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a)

open access: yesJACC: Advances
Background: Lipoprotein(a) [Lp(a)] has been independently associated with increased cardiovascular risk. Objectives: The authors examined the effect of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) on plasma Lp(a)
Frederick Berro Rivera, MD   +10 more
doaj  

PCSK9: a convertase that coordinates LDL catabolism

open access: yesJournal of Lipid Research, 2009
The identification and characterization of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) have provided new insights into LDL metabolism and the causal role of LDL in coronary heart disease (CHD).
Jay D. Horton   +2 more
doaj  

The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk [PDF]

open access: yes, 2016
Hypercholesterolaemia and dyslipidaemia, marked by decreased levels of high-density lipoprotein and elevated levels of lowdensity lipoprotein (LDL), increase the risk of cardiovascular disease.
Bronkhorst, E   +2 more
core   +1 more source

PACE4 (PCSK6): another proprotein convertase link to iron homeostasis?

open access: yesHaematologica, 2015
Johann Guillemot, Nabil G. Seidah
doaj   +1 more source

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation [PDF]

open access: green, 2003
Nabil G. Seidah   +8 more
openalex   +1 more source

The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis [PDF]

open access: bronze, 2003
Géraldine Siegfried   +7 more
openalex   +1 more source

Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes:A systematic review and meta-analysis [PDF]

open access: yes, 2019
Du, Heyue   +17 more
core   +2 more sources

Home - About - Disclaimer - Privacy